HBM Holdings Limited

2142

KYG4403H1002

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 11:36:01 2024-04-28 pm EDT			5-day change	1st Jan Change
1.29 ^HKD	+3.20%		+19.44%	-33.51%

Apr. 02	HBM Holdings Returns to Profitability in 2023	MT
Mar. 28	HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 07:19 am EDT

HBM Holdings Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 89.5 million compared to USD 40.66 million a year ago. Net income was USD 22.8 million compared to net loss of USD 137.22 million a year ago.

Basic earnings per share from continuing operations was USD 0.03 compared to basic loss per share from continuing operations of USD 0.19 a year ago. Diluted earnings per share from continuing operations was USD 0.03 compared to diluted loss per share from continuing operations of USD 0.19 a year ago.

Latest news about HBM Holdings Limited

HBM Holdings Returns to Profitability in 2023	Apr. 02	MT
HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
HBM Holdings Subsidiary Signs Antibody-Drug Conjugate Discovery Collaboration Deal	Feb. 27	MT
HBM Holdings Gets US FDA Clinical Trial Approval for Anti-Tumor Medication	Jan. 24	MT
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S	Jan. 23	CI
HBM to Swing to 2023 Profit	Jan. 19	MT
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023	Jan. 18	CI
HBM Holdings Limited commences an Equity Buyback Plan for 76,842,891 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023.	Dec. 19	CI
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	Dec. 15	MT
HBM Holdings Limited Announces Results of the Phase Iii Clinical Trial, Which Demonstrated That the Efficacy in the Primary and Secondary Endpoints of Batoclimab	Dec. 01	CI
HBM Holdings Limited Announces Executive Changes	23-10-19	CI
HBM Swings to Profit in H1; Shares Up 6%	23-08-29	MT
HBM Gets US FDA Clearance to Hold Anti-Tumor Drug Trials in US	23-08-29	MT
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors	23-08-28	CI
HBM Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	23-08-08	CI
HBM Arm Nona Expects Over $1.3 Billion from ADC Product	23-08-07	MT
HBM Holdings, Beigene Sign License Deal for Antibody-Drug Conjugate Program; HBM Shares Soar 20%	23-07-14	MT
HBM to Swing to H1 Profit Amid 45% Revenue Boost	23-07-13	MT
HBM Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023	23-07-13	CI
HBM Holdings Limited Announces Board Changes	23-07-13	CI
Drug Regulator Accepts HBM's Application for Batoclimab	23-06-30	MT
National Medical Products Administration of China Accepts Biologics License Application for HBM Holdings Limited's Batoclimab for Treatment of gMG	23-06-29	CI
HBM Holdings Limited Appoints Steve Arkinstall as Chief Scientific Advisor of Nona Biosciences	23-06-06	CI
Harbour BioMed Announces First Patient Dosed in Phase I Study of First-In-Class Anti-B7H7 Antibody HBM1020	23-06-04	CI

Chart HBM Holdings Limited

Duration

Period

More charts

Company Profile

HBM Holdings Ltd is an investment holding company mainly engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The Companyâs products include batoclimab, mainly used for immune thrombocytopenia (ITP), gravesâ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
HBM HOLDINGS LIMITED	-33.51%	117M
CSL LIMITED	-4.65%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals